MediFind
Condition

Adult T-Cell Leukemia

Symptoms, Doctors, Treatments, Research & More

Condition 101

What is the definition of Adult T-Cell Leukemia?

Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1). The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as “holes” on a standard bone x-ray), and skin lesions.  There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases). The best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. Medication may include CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone). In some patients, a bone marrow transplant may be recommended.

What are the alternative names for Adult T-Cell Leukemia?

  • ATLL
  • Adult T-cell leukaemia
  • Adult T-cell leukaemia/lymphoma (HTLV-1 positive)
  • Adult T-cell lymphoma

Top Global Doctors

GT
Elite
Graham P. Taylor
GB
OH
Elite
Olivier Hermine
Paris, 11, FR
AB
Elite
Ali A. Bazarbachi
Beirut, BA, LB
Masao Matsuoka
MM
Elite
Masao Matsuoka
Kumamoto, JP
KO
Elite
Koichi I. Ohshima
Kurume, 40, JP

Latest Research

Latest Advance
Study
  • Condition: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric Patient
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: CD19-CAR T Cells
  • Number of Patients: 1
  • Published —
This case report describes a pediatric patient with relapsed/refractory B-precursor acute lymphoblastic leukemia (BCP-ALL) who experienced a fatal intraocular relapse after initial response to CD19-CAR T-cell therapy.
Latest Advance
Study
  • Condition: Refractory Systemic Lupus Erythematosus
  • Journal: The New England journal of medicine
  • Treatment Used: Daratumumab
  • Number of Patients: 2
  • Published —
This case report describes the use of daratumumab in patients with life-threatening lupus.